Form 4: NeuroOne Medical Technologies Director Paul Buckman Acquires Shares and Options
SEC Form 4
Director Paul Buckman reports acquisition of NeuroOne Medical Technologies stock and options through grants.
Summary
- On February 14, 2025, Paul Buckman, a director of NeuroOne Medical Technologies Corp, acquired 27,778 shares of common stock and options to purchase 17,025 shares.
- The common stock was acquired at a price of $0.
- The options have an exercise price of $1.20 and expire on February 14, 2035.
- Both the stock and options vest in 12 equal monthly installments over one year.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports insider transactions without expressing any positive or negative outlook.
Positives
- The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of shares by a director may have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of transaction: Acquisition of common stock and options. |
| 02/14/2035 | Expiration date of the options. |
| 02/19/2025 | Date of signature for the Form 4 filing. |
Keywords
NeuroOne Medical Technologies, NMTC, Paul Buckman, Director, Stock Options, Common Stock, Acquisition, Form 4, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.